Explore
Validate
Learn
Western blotAntibody data
- Antibody Data
- Antigen structure
- References [8]
- Comments [0]
- Validations [0]
Submit
Validation data
Reference
Comment
Report error
- Product number
- 67663-1-Ig - Provider product page
- Provider
- Proteintech Group
- Product name
- IMPDH2 antibody
- Antibody type
- Monoclonal
- Description
- IMPDH2 antibody (Cat. #67663-1-Ig) is a mouse monoclonal antibody that shows reactivity with Human, mouse, rat and has been validated for the following applications: IF, IHC, WB,ELISA.
- Reactivity
- Human, Mouse, Rat
- Host
- Mouse
- Conjugate
- Unconjugated
- Isotype
- IgG
- Antibody clone number
- 1B1G8
- Vial size
- 20ul, 150ul
Submitted references tRF-1432 orchestrates RBMS1-IMPDH2 regulatory control to drive purine-dependent chemoresistance in breast cancer.
IMPDH2 facilitates CD4+ T cell activation through AKT/mTOR pathway by upregulating SRPK1 in myasthenia gravis.
Targeting IMPDH to inhibit SAMHD1 in KMT2A-rearranged leukaemia.
FDA-approved IMPDH inhibitors synergize with ribavirin to inhibit respiratory syncytial virus by interfering with purine de novo synthesis.
Epstein-Barr virus latent membrane protein 1 subverts IMPDH pathways to drive B-cell oncometabolism.
Epigenetic silencing of KCTD8 promotes hepatocellular carcinoma growth by activating PI3K/AKT signaling.
Hypoxia-induced TMTC3 expression in esophageal squamous cell carcinoma potentiates tumor angiogenesis through Rho GTPase/STAT3/VEGFA pathway.
Regulation of local GTP availability controls RAC1 activity and cell invasion.
Dai Y, Wu X, Cheng X, Shang J, Yu Z, Xia Y, Pei S, Kang Y, Jin J, Wang S, Xie H, Cui Y
Cancer letters 2026 May 28;646:218408
Cancer letters 2026 May 28;646:218408
IMPDH2 facilitates CD4+ T cell activation through AKT/mTOR pathway by upregulating SRPK1 in myasthenia gravis.
Ren Y, Wu T, Liu Z, Li L, Li Y, Xin G, Peng S, Niu J, Chen B, Cai H, Tian Q, Wang L, Zhang H
Clinical immunology (Orlando, Fla.) 2026 Jan;282:110634
Clinical immunology (Orlando, Fla.) 2026 Jan;282:110634
Targeting IMPDH to inhibit SAMHD1 in KMT2A-rearranged leukaemia.
Klootsema Y, Tsesmetzis N, Sharma S, Hofmann S, Thier J, Dirks C, Hormann FM, Yagüe-Capilla M, Bohlin A, Bengtzen S, Lehmann S, Chabes A, Jädersten M, Lundin V, Rudd SG, Lilienthal I, Herold N
Cell cycle (Georgetown, Tex.) 2026 Dec;25(1):1-19
Cell cycle (Georgetown, Tex.) 2026 Dec;25(1):1-19
FDA-approved IMPDH inhibitors synergize with ribavirin to inhibit respiratory syncytial virus by interfering with purine de novo synthesis.
Hu H, Wang Q, Ai Q, Zhou P, He Y, Ye Z, Ma K, Zhou M, Huang S, Wang L, Qi N, Xiao G, Wang S
Emerging microbes & infections 2026 Dec;15(1):2640289
Emerging microbes & infections 2026 Dec;15(1):2640289
Epstein-Barr virus latent membrane protein 1 subverts IMPDH pathways to drive B-cell oncometabolism.
Burton EM, Maestri D, White S, Liang JH, Mitra B, Asara JM, Gewurz BE
PLoS pathogens 2025 May;21(5):e1013092
PLoS pathogens 2025 May;21(5):e1013092
Epigenetic silencing of KCTD8 promotes hepatocellular carcinoma growth by activating PI3K/AKT signaling.
Zhou J, Zhang M, Gao A, Herman JG, Guo M
Epigenomics 2024;16(13):929-944
Epigenomics 2024;16(13):929-944
Hypoxia-induced TMTC3 expression in esophageal squamous cell carcinoma potentiates tumor angiogenesis through Rho GTPase/STAT3/VEGFA pathway.
Yuan H, Zhao Z, Xu J, Zhang R, Ma L, Han J, Zhao W, Guo M, Song Y
Journal of experimental & clinical cancer research : CR 2023 Sep 26;42(1):249
Journal of experimental & clinical cancer research : CR 2023 Sep 26;42(1):249
Regulation of local GTP availability controls RAC1 activity and cell invasion.
Bianchi-Smiraglia A, Wolff DW, Marston DJ, Deng Z, Han Z, Moparthy S, Wombacher RM, Mussell AL, Shen S, Chen J, Yun DH, O'Brien Cox A, Furdui CM, Hurley E, Feltri ML, Qu J, Hollis T, Kengne JBN, Fongang B, Sousa RJ, Kandel ME, Kandel ES, Hahn KM, Nikiforov MA
Nature communications 2021 Oct 19;12(1):6091
Nature communications 2021 Oct 19;12(1):6091
No comments: Submit comment
No validations: Submit validation data